Literature DB >> 27651315

BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.

Guillaume Andrieu1, Anna H Tran1, Katherine J Strissel1, Gerald V Denis2,3.   

Abstract

The bromodomain and extraterminal (BET) proteins are epigenetic "readers" of acetylated histones in chromatin and have been identified as promising therapeutic targets in diverse cancers. However, it remains unclear how individual family members participate in cancer progression and small molecule inhibitors such as JQ1 can target functionally independent BET proteins. Here, we report a signaling pathway involving BRD4 and the ligand/receptor pair Jagged1/Notch1 that sustains triple-negative breast cancer migration and invasion. BRD4, but not BRD2 or BRD3, regulated Jagged1 expression and Notch1 signaling. BRD4-selective knockdown suppressed Notch1 activity and impeded breast cancer migration and invasion. BRD4 was required for IL6-stimulated, Notch1-induced migration and invasion, coupling microenvironment inflammation with cancer propagation. Moreover, in patients, BRD4 and Jagged1 expression positively correlated with the presence of distant metastases. These results identify a BRD4/Jagged1/Notch1 signaling pathway that is critical for dissemination of triple-negative breast cancer. Cancer Res; 76(22); 6555-67. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27651315      PMCID: PMC5290198          DOI: 10.1158/0008-5472.CAN-16-0559

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.

Authors:  Mirjam C Boelens; Tony J Wu; Barzin Y Nabet; Bihui Xu; Yu Qiu; Taewon Yoon; Diana J Azzam; Christina Twyman-Saint Victor; Brianne Z Wiemann; Hemant Ishwaran; Petra J Ter Brugge; Jos Jonkers; Joyce Slingerland; Andy J Minn
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

4.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

5.  Bromodomain 4 activation predicts breast cancer survival.

Authors:  Nigel P S Crawford; Jude Alsarraj; Luanne Lukes; Renard C Walker; Jennifer S Officewala; Howard H Yang; Maxwell P Lee; Keiko Ozato; Kent W Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

6.  A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase.

Authors:  Tetsuo Maruyama; Andrea Farina; Anup Dey; JaeHun Cheong; Vladimir P Bermudez; Tomohiko Tamura; Selvaggia Sciortino; Jon Shuman; Jerard Hurwitz; Keiko Ozato
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

7.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

8.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.

Authors:  Lisa K Dunnwald; Mary Anne Rossing; Christopher I Li
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  BRD4 inhibitor inhibits colorectal cancer growth and metastasis.

Authors:  Yuan Hu; Jieqiong Zhou; Fei Ye; Huabao Xiong; Liang Peng; Zihan Zheng; Feihong Xu; Miao Cui; Chengguo Wei; Xinying Wang; Zhongqiu Wang; Hongfa Zhu; Peng Lee; Mingming Zhou; Bo Jiang; David Y Zhang
Journal:  Int J Mol Sci       Date:  2015-01-16       Impact factor: 5.923

10.  Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.

Authors:  Shaokun Shu; Charles Y Lin; Housheng Hansen He; Robert M Witwicki; Doris P Tabassum; Justin M Roberts; Michalina Janiszewska; Sung Jin Huh; Yi Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G Stover; Muhammad B Ekram; Jonathan Brown; Clive D'Santos; Ian E Krop; Deborah Dillon; Michael McKeown; Christopher Ott; Jun Qi; Min Ni; Prakash K Rao; Melissa Duarte; Shwu-Yuan Wu; Cheng-Ming Chiang; Lars Anders; Richard A Young; Eric Winer; Antony Letai; William T Barry; Jason S Carroll; Henry Long; Myles Brown; X Shirley Liu; Clifford A Meyer; James E Bradner; Kornelia Polyak
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

View more
  49 in total

Review 1.  Targeting forkhead box M1 transcription factor in breast cancer.

Authors:  Ruth M O'Regan; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2018-05-31       Impact factor: 5.858

2.  Effect of endovascular therapy on the expression levels of serum T lymphocyte subsets, Notch1 and TACE proteins in patients with abdominal aortic aneurysm.

Authors:  Hao Yan; Hong Jiang; Qian Xia; Wei Shan; Liwei Zhang; Fan Zhao
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.

Authors:  Jordan S Shafran; Guillaume P Andrieu; Balázs Györffy; Gerald V Denis
Journal:  Mol Cancer Res       Date:  2019-05-20       Impact factor: 5.852

4.  BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.

Authors:  Guillaume P Andrieu; Jordan S Shafran; Charlotte L Smith; Anna C Belkina; Allison N Casey; Naser Jafari; Gerald V Denis
Journal:  Cancer Lett       Date:  2019-08-29       Impact factor: 8.679

5.  Tumor microenvironment heterogeneity: challenges and opportunities.

Authors:  F Runa; S Hamalian; K Meade; P Shisgal; P C Gray; J A Kelber
Journal:  Curr Mol Biol Rep       Date:  2017-10-30

6.  BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.

Authors:  Guillaume P Andrieu; Gerald V Denis
Journal:  Mol Cancer Res       Date:  2018-02-07       Impact factor: 5.852

7.  BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.

Authors:  Qin Lu; Xiwei Ding; Tianlu Huang; Shu Zhang; Yang Li; Lei Xu; Gang Chen; Yuyao Ying; Yun Wang; Zhenqing Feng; Lei Wang; Xiaoping Zou
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 8.  BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.

Authors:  Guillaume P Andrieu; Jordan S Shafran; Jude T Deeney; Kishan R Bharadwaj; Annapoorni Rangarajan; Gerald V Denis
Journal:  J Leukoc Biol       Date:  2018-03-01       Impact factor: 4.962

Review 9.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

Review 10.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.